Sign in or create an account to add this stock to your watchlist.
About Heska (NASDAQ:HSKA)
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. The company sells its products to veterinarians through a field organization, a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HSKA
CUSIPN/A
Phone970-493-7272
Debt
Debt-to-Equity RatioN/A
Current Ratio2.68
Quick Ratio1.39
Price-To-Earnings
Trailing P/E Ratio49.17
Forward P/E Ratio60.59
P/E GrowthN/A
Sales & Book Value
Annual Sales$129.34 million
Price / Sales5.87
Cash Flow$2.8354 per share
Price / Cash35.90
Book Value$14.09 per share
Price / Book7.22
Profitability
EPS (Most Recent Fiscal Year)$2.07
Net Income$9.95 million
Net Margins5.57%
Return on Equity13.30%
Return on Assets10.01%
Miscellaneous
Employees345
Outstanding Shares7,460,000
Heska (NASDAQ:HSKA) Frequently Asked Questions
What is Heska's stock symbol?
Heska trades on the NASDAQ under the ticker symbol "HSKA."
How were Heska's earnings last quarter?
Heska Co. (NASDAQ:HSKA) issued its earnings results on Friday, May, 4th. The medical research company reported $0.28 EPS for the quarter, missing the Zacks' consensus estimate of $0.40 by $0.12. The medical research company earned $32.77 million during the quarter, compared to analysts' expectations of $31.65 million. Heska had a net margin of 5.57% and a return on equity of 13.30%. View Heska's Earnings History.
When is Heska's next earnings date?
What price target have analysts set for HSKA?
6 analysts have issued 1 year price targets for Heska's stock. Their forecasts range from $93.00 to $143.00. On average, they expect Heska's stock price to reach $114.90 in the next twelve months. View Analyst Ratings for Heska.
What are Wall Street analysts saying about Heska stock?
Here are some recent quotes from research analysts about Heska stock:
- 1. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (5/23/2018)
- 2. B. Riley analysts commented, "We expect Q3 results to be generally in line. We forecast revenue of $35.8 million and EPS of $0.40 versus consensus of $36.0 million and EPS of $0.41. We model revenue growth at 7.1%, reflecting ongoing momentum in core blood diagnostics within its Core Companion Animal Health offset by Other Vaccines, Pharmaceuticals and Products segment which pulled forward revenue last quarter (but expecting to finish off Q4 strong)." (10/27/2017)
Who are some of Heska's key competitors?
Some companies that are related to Heska include Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Repligen (RGEN), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX), Iovance Biotherapeutics (IOVA), Audentes Therapeutics (BOLD) and DBV Technologies (DBVT).
Who are Heska's key executives?
Heska's management team includes the folowing people:
- Mr. Kevin S. Wilson, CEO, Pres & Director (Age 46)
- Mr. Jason A. Napolitano, COO, Chief Strategist & Sec. (Age 50)
- Ms. Catherine Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 42)
- Mr. Steven M. Eyl, Exec. VP of Global Sales & Marketing (Age 52)
- Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 55)
Has Heska been receiving favorable news coverage?
Headlines about HSKA stock have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Heska earned a media sentiment score of 0.13 on Accern's scale. They also assigned media stories about the medical research company an impact score of 46.97 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Heska's major shareholders?
Heska's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.50%), Neuberger Berman Group LLC (8.67%), Park West Asset Management LLC (3.65%), Redmile Group LLC (3.20%), Dimensional Fund Advisors LP (2.57%) and Northern Trust Corp (1.65%). Company insiders that own Heska stock include Carol Wrenn, G Irwin Gordon, Jason A Napolitano, John Mcmahon, Kevin S Wilson, Michael J Mcginley, Nancy Wisnewski, Rod Lippincott, Sharon J Larson and Steve Asakowicz. View Institutional Ownership Trends for Heska.
Which institutional investors are selling Heska stock?
HSKA stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Park West Asset Management LLC, Russell Investments Group Ltd., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Neuberger Berman Group LLC, Citigroup Inc. and JPMorgan Chase & Co.. Company insiders that have sold Heska company stock in the last year include John Mcmahon, Michael J Mcginley, Nancy Wisnewski, Rod Lippincott and Steve Asakowicz. View Insider Buying and Selling for Heska.
Which institutional investors are buying Heska stock?
HSKA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Tygh Capital Management Inc., Redmile Group LLC, Millennium Management LLC, Citadel Advisors LLC, WINTON GROUP Ltd and GSA Capital Partners LLP. View Insider Buying and Selling for Heska.
How do I buy shares of Heska?
Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heska's stock price today?
One share of HSKA stock can currently be purchased for approximately $101.79.
How big of a company is Heska?
Heska has a market capitalization of $761.62 million and generates $129.34 million in revenue each year. The medical research company earns $9.95 million in net income (profit) each year or $2.07 on an earnings per share basis. Heska employs 345 workers across the globe.
How can I contact Heska?
Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]
MarketBeat Community Rating for Heska (HSKA)
MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe HSKA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Heska (NASDAQ:HSKA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Heska (NASDAQ HSKA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.70%
Institutional Ownership Percentage: 88.16%
Heska (NASDAQ HSKA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/29/2017 | Michael J Mcginley | Insider | Sell | 7,826 | $87.14 | $681,957.64 | 106,771 |  |
| 11/27/2017 | Michael J Mcginley | Insider | Sell | 1 | $88.54 | $88.54 | 106,771 | |
| 8/31/2017 | Nancy Wisnewski | EVP | Sell | 825 | $102.21 | $84,323.25 | 38,114 | |
| 8/30/2017 | John Mcmahon | CFO | Sell | 2,608 | $101.17 | $263,851.36 | 193 | |
| 6/1/2017 | Steve Asakowicz | EVP | Sell | 382 | $100.08 | $38,230.56 | 10,382 | |
| 5/31/2017 | Michael J Mcginley | Insider | Sell | 11,189 | $98.53 | $1,102,452.17 | 111,877 | |
| 5/31/2017 | Rod Lippincott | EVP | Sell | 11,227 | $98.00 | $1,100,246.00 | 11,292 | |
| 5/24/2017 | Jason A. Napolitano | COO | Sell | 5,000 | $100.50 | $502,500.00 | | |
| 5/24/2017 | Nancy Wisnewski | EVP | Sell | 250 | $100.17 | $25,042.50 | 38,901 | |
| 5/23/2017 | Carol Wrenn | Director | Sell | 1,630 | $96.95 | $158,028.50 | 6,174 | |
| 5/23/2017 | John Mcmahon | CFO | Sell | 587 | $97.00 | $56,939.00 | 295 | |
| 5/4/2017 | Sharon J Larson | Director | Buy | 1,000 | $90.00 | $90,000.00 | 3,294 | |
| 4/11/2017 | Jason A. Napolitano | COO | Sell | 1,100 | $102.98 | $113,278.00 | | |
| 4/10/2017 | Jason A. Napolitano | COO | Sell | 3,900 | $102.94 | $401,466.00 | | |
| 3/9/2017 | John Mcmahon | CFO | Sell | 708 | $97.42 | $68,973.36 | 200 | |
| 3/9/2017 | Rod Lippincott | EVP | Sell | 5,157 | $97.87 | $504,715.59 | 10,513 | |
| 3/6/2017 | Kevin S Wilson | CEO | Sell | 8,000 | $90.00 | $720,000.00 | 110,000 | |
| 1/10/2017 | Jason A. Napolitano | COO | Sell | 5,000 | $74.73 | $373,650.00 | | |
| 11/29/2016 | G Irwin Gordon | Director | Sell | 3,000 | $66.11 | $198,330.00 | 17,596 | |
| 11/28/2016 | John Mcmahon | CFO | Sell | 1,999 | $65.64 | $131,214.36 | 584 | |
| 11/22/2016 | Rod Lippincott | EVP | Sell | 5,000 | $64.85 | $324,250.00 | 10,192 | |
| 9/1/2016 | Jason A. Napolitano | CFO | Sell | 5,000 | $52.53 | $262,650.00 | | |
| 8/29/2016 | Kevin S Wilson | CEO | Sell | 20,000 | $51.80 | $1,036,000.00 | 110,000 | |
| 8/24/2016 | John Mcmahon | VP | Sell | 137 | $51.30 | $7,028.10 | | |
| 8/9/2016 | Steve Asakowicz | EVP | Sell | 4,698 | $52.55 | $246,879.90 | 12,858 | |
| 8/3/2016 | Kevin S Wilson | CEO | Sell | 30,736 | $47.34 | $1,455,042.24 | 140,720 | |
| 7/29/2016 | Kevin S Wilson | CEO | Sell | 20 | $43.95 | $879.00 | 140,736 | |
| 7/20/2016 | Kevin S Wilson | CEO | Sell | 3,779 | $44.02 | $166,351.58 | 140,756 | |
| 7/18/2016 | Kevin S Wilson | CEO | Sell | 5,465 | $44.31 | $242,154.15 | 144,535 | |
| 7/8/2016 | Kevin S Wilson | CEO | Sell | 10,000 | $42.37 | $423,700.00 | 150,000 | |
| 7/7/2016 | Jason A. Napolitano | CFO | Sell | 20,000 | $41.00 | $820,000.00 | | |
| 7/6/2016 | Kevin S Wilson | CEO | Sell | 5,960 | $40.27 | $240,009.20 | 160,000 | |
| 7/1/2016 | Kevin S Wilson | CEO | Sell | 14,040 | $38.94 | $546,717.60 | 165,960 | |
| 6/2/2016 | Kevin S Wilson | CEO | Sell | 20,000 | $36.74 | $734,800.00 | 190,000 | |
| 5/12/2016 | Kevin S Wilson | CEO | Sell | 5,000 | $38.50 | $192,500.00 | 200,000 | |
| 5/10/2016 | Kevin S Wilson | CEO | Sell | 15,000 | $36.75 | $551,250.00 | 210,000 | |
| 5/10/2016 | Michael J Mcginley | Insider | Sell | 5,998 | $36.50 | $218,927.00 | 30,801 | |
| 5/10/2016 | Sharon L Riley | Director | Sell | 5,000 | $36.87 | $184,350.00 | 9,500 | |
| 5/9/2016 | Kevin S Wilson | CEO | Sell | 11,000 | $35.61 | $391,710.00 | 228,718 | |
| 5/5/2016 | Sharon L Riley | Director | Sell | 15,000 | $35.66 | $534,900.00 | 9,500 | |
| 5/3/2016 | Jason A Napolitano | CFO | Sell | 5,000 | $35.75 | $178,750.00 | 63,544 | |
| 3/8/2016 | Sharon L Riley | Director | Buy | 1,000 | $32.49 | $32,490.00 | 5,500 | |
| 1/27/2016 | Jason A Napolitano | CFO | Sell | 15,000 | $37.00 | $555,000.00 | 51,900 | |
| 12/29/2015 | Jason A. Napolitano | CFO | Sell | 3,700 | $40.03 | $148,111.00 | 66,900 | |
| 12/3/2015 | Kevin S Wilson | CEO | Sell | 6,000 | $35.50 | $213,000.00 | 230,000 | |
| 11/25/2015 | Michael J. Mcginley | insider | Sell | 958 | $33.62 | $32,207.96 | 15,928 | |
| 11/24/2015 | Michael J. Mcginley | insider | Sell | 1,427 | $33.33 | $47,561.91 | 15,928 | |
| 9/11/2015 | Jason A Napolitano | CFO | Sell | 1,699 | $33.51 | $56,933.49 | 58,100 | |
| 8/31/2015 | Jason A. Napolitano | CFO | Sell | 4,998 | $33.59 | $167,882.82 | 59,799 | |
| 8/31/2015 | Robert B. Grieve | insider | Sell | 11,098 | $33.77 | $374,779.46 | 101,690 | |
| 8/27/2015 | Robert B. Grieve | insider | Sell | 3,604 | $33.79 | $121,779.16 | 101,690 | |
| 8/17/2015 | Kevin S Wilson | CEO | Sell | 2,498 | $34.90 | $87,180.20 | | |
| 8/17/2015 | Robert B Grieve | Insider | Sell | 8,033 | $34.91 | $280,432.03 | | |
| 8/14/2015 | Kevin S Wilson | CEO | Sell | 2,101 | $34.90 | $73,324.90 | | |
| 8/14/2015 | Rod Lippincott | EVP | Sell | 3,898 | $34.19 | $133,272.62 | | |
| 7/13/2015 | Robert B Grieve | Insider | Sell | 1,000 | $29.99 | $29,990.00 | | |
| 6/8/2015 | Kevin S Wilson | CEO | Sell | 11,810 | $30.08 | $355,244.80 | | |
| 6/3/2015 | Robert B Grieve | Insider | Sell | 17,000 | $31.36 | $533,120.00 | | |
| 6/1/2015 | Jason A Napolitano | CFO | Sell | 7,536 | $32.26 | $243,111.36 | | |
| 5/22/2015 | Steven M Eyl | EVP | Sell | 5,981 | $30.19 | $180,566.39 | | |
| 4/24/2015 | Robert B Grieve | Insider | Sell | 6,000 | $29.67 | $178,020.00 | | |
| 4/13/2015 | Robert B Grieve | Insider | Sell | 4,000 | $26.54 | $106,160.00 | | |
| 3/9/2015 | Jason A Napolitano | CFO | Sell | 5,765 | $26.02 | $150,005.30 | | |
| 3/9/2015 | Kevin S Wilson | CEO | Sell | 10,000 | $25.38 | $253,800.00 | | |
| 3/9/2015 | Robert B Grieve | Insider | Sell | 2,000 | $25.26 | $50,520.00 | | |
| 11/30/2014 | David E Sveen | Director | Buy | 21,428 | $14.00 | $299,992.00 | | |
| 11/30/2014 | Kevin S Wilson | CEO | Sell | 28,928 | $14.00 | $404,992.00 | | |
| 11/21/2014 | Robert B Grieve | Insider | Sell | 6,500 | $15.25 | $99,125.00 | | |
| 11/3/2014 | William A Aylesworth | Director | Sell | 5,000 | $13.67 | $68,350.00 | | |
| 8/4/2014 | Robert B Grieve | Director | Sell | 12,000 | $13.57 | $162,840.00 | | |
| 5/14/2014 | William Aylesworth | Director | Sell | 4,200 | $10.89 | $45,738.00 | 29,797 | |
| 3/31/2014 | Carol Wrenn | Director | Buy | 1,000 | $10.50 | $10,500.00 | 4,000 | |
| 3/31/2014 | Robert Grieve | CEO | Sell | 7,000 | $10.50 | $73,500.00 | 143 | |
| 3/1/2013 | William A Aylesworth | Director | Buy | 2,000 | $8.34 | $16,680.00 | | |
| 10/3/2012 | Master Fund L.P. Cmc | Major Shareholder | Sell | 11,002 | $9.54 | $104,959.08 | | |
| 8/28/2012 | William A Aylesworth | Director | Buy | 2,000 | $7.95 | $15,900.00 | | |
(Data available from 1/1/2013 forward)
Heska (NASDAQ HSKA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Heska Co. (HSKA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 25 at 1:40 PM |
 | Recent Analysis Shows Alexander's, American National Insurance, VAREX IMAGING, Banner, Instructure,
www.nasdaq.com - May 24 at 8:33 AM |
| Analysts Anticipate Heska Co. (HSKA) Will Announce Quarterly Sales of $30.19 Million
www.americanbankingnews.com - May 24 at 2:14 AM |
| Zacks: Analysts Anticipate Heska Co. (HSKA) to Announce $0.17 EPS
www.americanbankingnews.com - May 22 at 7:18 PM |
| Benchmark Raises Heska (HSKA) Price Target to $143.00
www.americanbankingnews.com - May 21 at 11:25 AM |
| Heska Co. to Post Q4 2018 Earnings of $0.79 Per Share, B. Riley Forecasts (HSKA)
www.americanbankingnews.com - May 21 at 1:26 AM |
 | Heska: Pets Are People Too
seekingalpha.com - May 18 at 5:39 PM |
| Canaccord Genuity Reaffirms Buy Rating for Heska (HSKA)
www.americanbankingnews.com - May 18 at 5:13 PM |
| Heska (HSKA) Price Target Raised to $93.00
www.americanbankingnews.com - May 18 at 4:13 PM |
 | Wired News – Heska Collaborates with MBio Diagnostics for Developing New Products for the Veterinary Market
finance.yahoo.com - May 17 at 8:39 AM |
| Heska: Margin Expansion Opportunity
seekingalpha.com - May 9 at 5:19 PM |
| B. Riley Comments on Heska Co.'s Q2 2018 Earnings (HSKA)
www.americanbankingnews.com - May 9 at 8:45 AM |
| Heska (HSKA) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 8 at 10:22 AM |
| B. Riley Comments on Heska Co.'s Q3 2018 Earnings (HSKA)
www.americanbankingnews.com - May 8 at 7:12 AM |
| Heska (HSKA) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - May 7 at 2:57 PM |
| Heska (HSKA) Price Target Raised to $100.00 at Benchmark
www.americanbankingnews.com - May 7 at 2:56 PM |
| $33.75 Million in Sales Expected for Heska Co. (HSKA) This Quarter
www.americanbankingnews.com - May 7 at 4:23 AM |
| Heska's (HSKA) CEO Kevin Wilson on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:23 PM |
| Heska (HSKA) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 5 at 2:27 PM |
| Heska Co. (HSKA) Expected to Post Earnings of $0.50 Per Share
www.americanbankingnews.com - May 5 at 11:37 AM |
 | Heska (HSKA) Misses Q1 EPS by 7c
www.streetinsider.com - May 5 at 8:43 AM |
| Edited Transcript of HSKA earnings conference call or presentation 4-May-18 3:00pm GMT
finance.yahoo.com - May 5 at 8:43 AM |
| Heska (HSKA) Issues Earnings Results
www.americanbankingnews.com - May 4 at 8:33 PM |
 | BRIEF-Heska Reports Q1 Earnings Per Share Of $0.28
www.reuters.com - May 4 at 5:15 PM |
| Heska misses by $0.07, beats on revenue
seekingalpha.com - May 4 at 8:32 AM |
| Heska Reports First Quarter Results
finance.yahoo.com - May 4 at 8:32 AM |
| Heska: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:32 AM |
| Heska (HSKA) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 3 at 11:51 PM |
| Why Heska (HSKA) Might Surprise This Earnings Season
finance.yahoo.com - May 3 at 5:11 PM |
| Heska to Present at Upcoming Conferences in May & June 2018
finance.yahoo.com - May 3 at 8:30 AM |
| Heska Corporation Announces Board Action
finance.yahoo.com - May 2 at 5:23 PM |
| Heska to Host Analyst and Investor Day on May 15
finance.yahoo.com - May 2 at 8:36 AM |
| Heska Co. (HSKA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 30 at 1:36 PM |
| Heska Names EVP, International Diagnostics, to Accelerate International Expansion
finance.yahoo.com - April 30 at 8:38 AM |
| Heska (HSKA) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - April 27 at 1:16 AM |
| Head to Head Contrast: Heska (HSKA) and Its Competitors
www.americanbankingnews.com - April 25 at 5:16 PM |
| Heska Confirms Details for Annual Meeting of Stockholders on May 3, 2018
finance.yahoo.com - April 25 at 8:33 AM |
| Head-To-Head Review: Heska (HSKA) vs. Solid Biosciences (SLDB)
www.americanbankingnews.com - April 25 at 3:06 AM |
| Heska (HSKA) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM |
| $31.65 Million in Sales Expected for Heska Co. (HSKA) This Quarter
www.americanbankingnews.com - April 20 at 4:02 AM |
| Heska Co. (HSKA) Expected to Announce Earnings of $0.40 Per Share
www.americanbankingnews.com - April 18 at 9:22 AM |
| Comparing Heska (HSKA) and The Competition
www.americanbankingnews.com - April 16 at 11:10 PM |
| Heska (HSKA) Earns Neutral Rating from B. Riley
www.americanbankingnews.com - April 13 at 9:58 PM |
| Heska (HSKA) PT Raised to $120.00
www.americanbankingnews.com - April 13 at 5:29 PM |
| Heska (HSKA) Upgraded at BidaskClub
www.americanbankingnews.com - April 13 at 4:23 PM |
| Heska: Attractive Opportunity
seekingalpha.com - April 12 at 5:21 PM |
| Heska (HSKA) Receives "Buy" Rating from Benchmark
www.americanbankingnews.com - April 12 at 3:58 PM |
| Heska (HSKA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 3:54 PM |
| Heska Schedules First Quarter 2018 Financial Results Conference Call for May 4, 2018
finance.yahoo.com - April 10 at 8:48 AM |
| Analyzing Heska (HSKA) and Its Competitors
www.americanbankingnews.com - April 8 at 3:08 AM |
Heska (NASDAQ:HSKA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Heska (NASDAQ:HSKA) Income Statement, Balance Sheet and Cash Flow Statement
Heska (NASDAQ HSKA) Stock Chart for Saturday, May, 26, 2018
Loading chart…
